Home » Topics » BioWorld Science

BioWorld Science
RSS

VX-548 enters phase II development for the treatment of acute pain

July 20, 2021

Loss-of-function variant in SUV39H2 identified in autism spectrum disorder

July 20, 2021

Prometheus initiates phase II ARTEMIS-UC study of PRA-023

July 20, 2021

DSMB recommends continued treatment in phase II portion of OVATION 2 study with GEN-1

July 20, 2021

iOnctura initiates clinical development of next-generation autotaxin inhibitor IOA-289

July 20, 2021

SRI International describes lipoxygenase inhibitors

July 20, 2021

Angex Pharmaceutical synthesizes new mTOR inhibitors

July 20, 2021

Positive topline data reported from phase II REDWOOD-HCM study of CK-274

July 20, 2021

Sitryx Therapeutics presents new NFE2L2 activators

July 20, 2021

Sumitomo Dainippon Pharma divulges 5-HT2A and/or 5-HT7 receptor antagonists

July 20, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 11, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026